Nektar Therapeutics (NKTR)
- Previous Close
1.6000 - Open
1.6500 - Bid 1.7400 x 900
- Ask 1.7700 x 800
- Day's Range
1.6300 - 1.8700 - 52 Week Range
0.4100 - 1.8700 - Volume
2,350,957 - Avg. Volume
2,579,112 - Market Cap (intraday)
323.178M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4500 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
www.nektar.comRecent News: NKTR
Performance Overview: NKTR
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKTR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKTR
Valuation Measures
Market Cap
323.18M
Enterprise Value
137.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.71
Price/Book (mrq)
2.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.25%
Return on Equity (ttm)
-110.95%
Revenue (ttm)
90.12M
Net Income Avi to Common (ttm)
-276.06M
Diluted EPS (ttm)
-1.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
303.62M
Total Debt/Equity (mrq)
175.90%
Levered Free Cash Flow (ttm)
-63.63M
Research Analysis: NKTR
Company Insights: NKTR
NKTR does not have Company Insights